Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
47
SPRY Quote, Financials, Valuation and Earnings
Last price:
$9.98
Seasonality move
:
7.95%
Day range:
$9.44 - $10.02
52-week range:
$6.66 - $18.90
Dividend yield:
0%
P/E ratio:
174.21x
P/S ratio:
6.86x
P/B ratio:
6.67x
Volume:
1.4M
Avg. volume:
2.2M
1-year change:
-30.86%
Market cap:
$985.5M
Revenue:
$89.1M
EPS (TTM):
-$0.81
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SPRY
ARS Pharmaceuticals, Inc.
|
$28.7M | -$0.49 | -69.68% | -148.61% | $28.67 |
|
AMGN
Amgen, Inc.
|
$9B | $5.01 | 4.56% | 309.55% | $324.25 |
|
ATYR
aTyr Pharma, Inc.
|
-- | -$0.19 | -100% | -5.03% | $4.36 |
|
IDYA
IDEAYA Biosciences, Inc.
|
$60M | -$0.55 | -15.05% | -37.84% | $49.47 |
|
KALV
KalVista Pharmaceuticals, Inc.
|
$4.2M | -$1.04 | -- | -18.07% | $31.00 |
|
LPCN
Lipocine, Inc.
|
$238K | -- | -96.68% | -- | $6.88 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SPRY
ARS Pharmaceuticals, Inc.
|
$9.97 | $28.67 | $985.5M | 174.21x | $0.00 | 0% | 6.86x |
|
AMGN
Amgen, Inc.
|
$340.16 | $324.25 | $183.2B | 26.30x | $2.38 | 2.8% | 5.13x |
|
ATYR
aTyr Pharma, Inc.
|
$0.83 | $4.36 | $81.1M | -- | $0.00 | 0% | 388.29x |
|
IDYA
IDEAYA Biosciences, Inc.
|
$36.01 | $49.47 | $3.2B | -- | $0.00 | 0% | 14.83x |
|
KALV
KalVista Pharmaceuticals, Inc.
|
$16.40 | $31.00 | $829M | -- | $0.00 | 0% | 56.89x |
|
LPCN
Lipocine, Inc.
|
$3.10 | $6.88 | $17.2M | -- | $0.00 | 0% | 3.85x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SPRY
ARS Pharmaceuticals, Inc.
|
39.84% | 0.374 | 9.84% | 6.38x |
|
AMGN
Amgen, Inc.
|
85.02% | 0.027 | 35.92% | 0.82x |
|
ATYR
aTyr Pharma, Inc.
|
13.35% | 1.243 | 17.53% | 5.75x |
|
IDYA
IDEAYA Biosciences, Inc.
|
2.43% | 1.755 | 1.14% | 12.20x |
|
KALV
KalVista Pharmaceuticals, Inc.
|
94.33% | -1.515 | 45.9% | 6.99x |
|
LPCN
Lipocine, Inc.
|
-- | -0.532 | -- | 7.84x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SPRY
ARS Pharmaceuticals, Inc.
|
$24.3M | -$53.2M | -35.53% | -38.98% | -163.66% | -$47.2M |
|
AMGN
Amgen, Inc.
|
$6.5B | $2.6B | 10.74% | 95.55% | 26.65% | $4.2B |
|
ATYR
aTyr Pharma, Inc.
|
-$199K | -$26.7M | -87.48% | -103.05% | -14076.32% | -$20.5M |
|
IDYA
IDEAYA Biosciences, Inc.
|
$206.8M | $108.5M | -14.79% | -15.12% | 52.18% | $142.2M |
|
KALV
KalVista Pharmaceuticals, Inc.
|
$12.5M | -$46.1M | -97.51% | -243.25% | -336.33% | -$54.8M |
|
LPCN
Lipocine, Inc.
|
$100.5K | -$3.4M | -30.22% | -30.22% | -2932.81% | -$3M |
ARS Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns SPRY or AMGN?
Amgen, Inc. has a net margin of -157.38% compared to ARS Pharmaceuticals, Inc.'s net margin of 33.55%. ARS Pharmaceuticals, Inc.'s return on equity of -38.98% beat Amgen, Inc.'s return on equity of 95.55%.
Company Gross Margin Earnings Per Share Invested Capital SPRYARS Pharmaceuticals, Inc.74.8% -$0.52 $245.4M AMGNAmgen, Inc.67.85% $5.93 $64.2B -
What do Analysts Say About SPRY or AMGN?
ARS Pharmaceuticals, Inc. has a consensus price target of $28.67, signalling upside risk potential of 187.53%. On the other hand Amgen, Inc. has an analysts' consensus of $324.25 which suggests that it could fall by -4.68%. Given that ARS Pharmaceuticals, Inc. has higher upside potential than Amgen, Inc., analysts believe ARS Pharmaceuticals, Inc. is more attractive than Amgen, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SPRYARS Pharmaceuticals, Inc.6 0 0 AMGNAmgen, Inc.10 15 2 -
Is SPRY or AMGN More Risky?
ARS Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Amgen, Inc. has a beta of 0.451, suggesting its less volatile than the S&P 500 by 54.893%.
-
Which is a Better Dividend Stock SPRY or AMGN?
ARS Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amgen, Inc. offers a yield of 2.8% to investors and pays a quarterly dividend of $2.38 per share. ARS Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Amgen, Inc. pays out 119.05% of its earnings as a dividend.
-
Which has Better Financial Ratios SPRY or AMGN?
ARS Pharmaceuticals, Inc. quarterly revenues are $32.5M, which are smaller than Amgen, Inc. quarterly revenues of $9.6B. ARS Pharmaceuticals, Inc.'s net income of -$51.2M is lower than Amgen, Inc.'s net income of $3.2B. Notably, ARS Pharmaceuticals, Inc.'s price-to-earnings ratio is 174.21x while Amgen, Inc.'s PE ratio is 26.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ARS Pharmaceuticals, Inc. is 6.86x versus 5.13x for Amgen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SPRYARS Pharmaceuticals, Inc.6.86x 174.21x $32.5M -$51.2M AMGNAmgen, Inc.5.13x 26.30x $9.6B $3.2B
-
Which has Higher Returns SPRY or ATYR?
aTyr Pharma, Inc. has a net margin of -157.38% compared to ARS Pharmaceuticals, Inc.'s net margin of -13550.53%. ARS Pharmaceuticals, Inc.'s return on equity of -38.98% beat aTyr Pharma, Inc.'s return on equity of -103.05%.
Company Gross Margin Earnings Per Share Invested Capital SPRYARS Pharmaceuticals, Inc.74.8% -$0.52 $245.4M ATYRaTyr Pharma, Inc.-104.74% -$0.27 $92.4M -
What do Analysts Say About SPRY or ATYR?
ARS Pharmaceuticals, Inc. has a consensus price target of $28.67, signalling upside risk potential of 187.53%. On the other hand aTyr Pharma, Inc. has an analysts' consensus of $4.36 which suggests that it could grow by 426.35%. Given that aTyr Pharma, Inc. has higher upside potential than ARS Pharmaceuticals, Inc., analysts believe aTyr Pharma, Inc. is more attractive than ARS Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SPRYARS Pharmaceuticals, Inc.6 0 0 ATYRaTyr Pharma, Inc.1 7 0 -
Is SPRY or ATYR More Risky?
ARS Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison aTyr Pharma, Inc. has a beta of 0.572, suggesting its less volatile than the S&P 500 by 42.802%.
-
Which is a Better Dividend Stock SPRY or ATYR?
ARS Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. aTyr Pharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ARS Pharmaceuticals, Inc. pays -- of its earnings as a dividend. aTyr Pharma, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SPRY or ATYR?
ARS Pharmaceuticals, Inc. quarterly revenues are $32.5M, which are larger than aTyr Pharma, Inc. quarterly revenues of $190K. ARS Pharmaceuticals, Inc.'s net income of -$51.2M is lower than aTyr Pharma, Inc.'s net income of -$25.7M. Notably, ARS Pharmaceuticals, Inc.'s price-to-earnings ratio is 174.21x while aTyr Pharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ARS Pharmaceuticals, Inc. is 6.86x versus 388.29x for aTyr Pharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SPRYARS Pharmaceuticals, Inc.6.86x 174.21x $32.5M -$51.2M ATYRaTyr Pharma, Inc.388.29x -- $190K -$25.7M
-
Which has Higher Returns SPRY or IDYA?
IDEAYA Biosciences, Inc. has a net margin of -157.38% compared to ARS Pharmaceuticals, Inc.'s net margin of 57.38%. ARS Pharmaceuticals, Inc.'s return on equity of -38.98% beat IDEAYA Biosciences, Inc.'s return on equity of -15.12%.
Company Gross Margin Earnings Per Share Invested Capital SPRYARS Pharmaceuticals, Inc.74.8% -$0.52 $245.4M IDYAIDEAYA Biosciences, Inc.99.5% $1.33 $1.1B -
What do Analysts Say About SPRY or IDYA?
ARS Pharmaceuticals, Inc. has a consensus price target of $28.67, signalling upside risk potential of 187.53%. On the other hand IDEAYA Biosciences, Inc. has an analysts' consensus of $49.47 which suggests that it could grow by 37.38%. Given that ARS Pharmaceuticals, Inc. has higher upside potential than IDEAYA Biosciences, Inc., analysts believe ARS Pharmaceuticals, Inc. is more attractive than IDEAYA Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SPRYARS Pharmaceuticals, Inc.6 0 0 IDYAIDEAYA Biosciences, Inc.13 2 0 -
Is SPRY or IDYA More Risky?
ARS Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison IDEAYA Biosciences, Inc. has a beta of 0.040, suggesting its less volatile than the S&P 500 by 96.023%.
-
Which is a Better Dividend Stock SPRY or IDYA?
ARS Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IDEAYA Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ARS Pharmaceuticals, Inc. pays -- of its earnings as a dividend. IDEAYA Biosciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SPRY or IDYA?
ARS Pharmaceuticals, Inc. quarterly revenues are $32.5M, which are smaller than IDEAYA Biosciences, Inc. quarterly revenues of $207.8M. ARS Pharmaceuticals, Inc.'s net income of -$51.2M is lower than IDEAYA Biosciences, Inc.'s net income of $119.2M. Notably, ARS Pharmaceuticals, Inc.'s price-to-earnings ratio is 174.21x while IDEAYA Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ARS Pharmaceuticals, Inc. is 6.86x versus 14.83x for IDEAYA Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SPRYARS Pharmaceuticals, Inc.6.86x 174.21x $32.5M -$51.2M IDYAIDEAYA Biosciences, Inc.14.83x -- $207.8M $119.2M
-
Which has Higher Returns SPRY or KALV?
KalVista Pharmaceuticals, Inc. has a net margin of -157.38% compared to ARS Pharmaceuticals, Inc.'s net margin of -361.39%. ARS Pharmaceuticals, Inc.'s return on equity of -38.98% beat KalVista Pharmaceuticals, Inc.'s return on equity of -243.25%.
Company Gross Margin Earnings Per Share Invested Capital SPRYARS Pharmaceuticals, Inc.74.8% -$0.52 $245.4M KALVKalVista Pharmaceuticals, Inc.91% -$0.92 $299.6M -
What do Analysts Say About SPRY or KALV?
ARS Pharmaceuticals, Inc. has a consensus price target of $28.67, signalling upside risk potential of 187.53%. On the other hand KalVista Pharmaceuticals, Inc. has an analysts' consensus of $31.00 which suggests that it could grow by 89.02%. Given that ARS Pharmaceuticals, Inc. has higher upside potential than KalVista Pharmaceuticals, Inc., analysts believe ARS Pharmaceuticals, Inc. is more attractive than KalVista Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SPRYARS Pharmaceuticals, Inc.6 0 0 KALVKalVista Pharmaceuticals, Inc.7 0 0 -
Is SPRY or KALV More Risky?
ARS Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison KalVista Pharmaceuticals, Inc. has a beta of -0.135, suggesting its less volatile than the S&P 500 by 113.476%.
-
Which is a Better Dividend Stock SPRY or KALV?
ARS Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. KalVista Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ARS Pharmaceuticals, Inc. pays -- of its earnings as a dividend. KalVista Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SPRY or KALV?
ARS Pharmaceuticals, Inc. quarterly revenues are $32.5M, which are larger than KalVista Pharmaceuticals, Inc. quarterly revenues of $13.7M. ARS Pharmaceuticals, Inc.'s net income of -$51.2M is lower than KalVista Pharmaceuticals, Inc.'s net income of -$49.5M. Notably, ARS Pharmaceuticals, Inc.'s price-to-earnings ratio is 174.21x while KalVista Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ARS Pharmaceuticals, Inc. is 6.86x versus 56.89x for KalVista Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SPRYARS Pharmaceuticals, Inc.6.86x 174.21x $32.5M -$51.2M KALVKalVista Pharmaceuticals, Inc.56.89x -- $13.7M -$49.5M
-
Which has Higher Returns SPRY or LPCN?
Lipocine, Inc. has a net margin of -157.38% compared to ARS Pharmaceuticals, Inc.'s net margin of -2780.8%. ARS Pharmaceuticals, Inc.'s return on equity of -38.98% beat Lipocine, Inc.'s return on equity of -30.22%.
Company Gross Margin Earnings Per Share Invested Capital SPRYARS Pharmaceuticals, Inc.74.8% -$0.52 $245.4M LPCNLipocine, Inc.87.7% -$0.59 $14.1M -
What do Analysts Say About SPRY or LPCN?
ARS Pharmaceuticals, Inc. has a consensus price target of $28.67, signalling upside risk potential of 187.53%. On the other hand Lipocine, Inc. has an analysts' consensus of $6.88 which suggests that it could grow by 121.77%. Given that ARS Pharmaceuticals, Inc. has higher upside potential than Lipocine, Inc., analysts believe ARS Pharmaceuticals, Inc. is more attractive than Lipocine, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SPRYARS Pharmaceuticals, Inc.6 0 0 LPCNLipocine, Inc.2 0 0 -
Is SPRY or LPCN More Risky?
ARS Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Lipocine, Inc. has a beta of 1.027, suggesting its more volatile than the S&P 500 by 2.738%.
-
Which is a Better Dividend Stock SPRY or LPCN?
ARS Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lipocine, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ARS Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Lipocine, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SPRY or LPCN?
ARS Pharmaceuticals, Inc. quarterly revenues are $32.5M, which are larger than Lipocine, Inc. quarterly revenues of $114.6K. ARS Pharmaceuticals, Inc.'s net income of -$51.2M is lower than Lipocine, Inc.'s net income of -$3.2M. Notably, ARS Pharmaceuticals, Inc.'s price-to-earnings ratio is 174.21x while Lipocine, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ARS Pharmaceuticals, Inc. is 6.86x versus 3.85x for Lipocine, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SPRYARS Pharmaceuticals, Inc.6.86x 174.21x $32.5M -$51.2M LPCNLipocine, Inc.3.85x -- $114.6K -$3.2M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Buy
54
SMX alert for Dec 5
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 22.58% over the past day.
Buy
67
NUTX alert for Dec 5
Nutex Health, Inc. [NUTX] is up 18.9% over the past day.
